ADULT T-CELL LEUKEMIA/LYMPHOMA
Clinical trials for ADULT T-CELL LEUKEMIA/LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ADULT T-CELL LEUKEMIA/LYMPHOMA trials appear
Sign up with your email to follow new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare leukemia? drug combo trial launches
Disease control TerminatedThis early-stage trial tests adding lenalidomide to standard chemotherapy (EPOCH) for adult T-cell leukemia-lymphoma, a rare and aggressive blood cancer linked to HTLV-1 infection. The goal is to find the safest dose and see if the combination works better than chemo alone. About…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:08 UTC
-
New combo therapy shows promise against hard-to-treat t-cell lymphoma
Disease control OngoingThis study tested a combination of a targeted drug (brentuximab vedotin) and chemotherapy in 48 adults with a rare, aggressive lymphoma called CD30-positive peripheral T-cell lymphoma. The goal was to see how well the treatment shrinks tumors and what side effects occur. Particip…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 08:55 UTC
-
New drug combo targets tough T-Cell lymphoma
Disease control TerminatedThis early-stage study tests whether combining two existing drugs, azacitidine and abatacept, can shrink tumors in people with T-cell lymphoma that has come back or not responded to prior therapy. About 20 adults will receive the drugs in 28-day cycles for up to 13 cycles. The go…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
New hope for Tough-to-Treat lymphoma: experimental drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests a drug called valemetostat tosylate in people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not improved after other treatments. About 155 adults will take the drug and be monitored for tumor shrinkage and side effects. The go…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 13, 2026 16:01 UTC